Overview
Primary endpoint of this study is to evaluate the pharmacokinetic characteristics of AD-104-A
Description
The purpose of this study is to evaluate the pharmacokinetic characteristics of AD-104-A in Healthy Adult Volunteers and Patients with Renal Impairment
Eligibility
Inclusion Criteria:
For all subjects
- Adults aged 19 years and older
- Body mass index(BMI) of 18 to 30 kg/m2
- Voluntarily given written informed consent
For renal Impairment subjects
- 30 ≤ eGFR < 90 mL/min/1.73m^2
For healthy subjects
- eGFR ≥ 90 mL/min/1.73m^2
Exclusion Criteria:
- Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration
- Other exclusions applied
